Valuation : Verastem, Inc.

Market Cap 663M 571M 541M 490M 920M 63.33B 924M 6.42B 2.47B 32.22B 2.49B 2.44B 102B P/E 2026 *
-4.57x
P/E 2027 * -6.28x
Enterprise Value 705M 607M 575M 521M 978M 67.34B 983M 6.83B 2.63B 34.26B 2.65B 2.59B 108B EV / Sales 2026 *
6.05x
EV / Sales 2027 * 3.66x
Free-Float
98.98%
Yield 2026 *
-
Yield 2027 * -
1 day-3.94%
1 week-10.73%
Current month+1.39%
1 month+5.32%
3 months+78.54%
6 months+25.34%
Current year-5.18%
1 week 7.32
Extreme 7.315
8.54
1 month 6.44
Extreme 6.44
8.54
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/05/26 Free

Director

108,000 0.1229%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-3.94%-10.73%-24.69%-25.38% 663M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.66%-3.73%+25.12%+220.18% 27.11B
Weighted average by Cap. -0.56%-2.85%+31.12%+170.17%

Financials

2026 *2027 *
Net sales 116M 100M 95M 86.11M 162M 11.12B 162M 1.13B 434M 5.66B 437M 428M 17.88B 181M 156M 148M 134M 251M 17.3B 253M 1.76B 675M 8.8B 680M 665M 27.82B
Net income -166M -143M -135M -123M -230M -15.85B -231M -1.61B -618M -8.06B -623M -609M -25.48B -157M -135M -128M -116M -218M -15B -219M -1.52B -585M -7.63B -590M -577M -24.12B
Net Debt 41.9M 36.1M 34.18M 30.98M 58.13M 4B 58.42M 406M 156M 2.04B 157M 154M 6.44B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
11/09/26 $7.320 -3.94% 1,913,863
10/09/26 $7.620 -4.03% 2,670,005
09/09/26 $7.940 -1.73% 2,400,611
08/09/26 $8.080 -1.46% 4,366,392
04/09/26 $8.200 +2.76% 2,301,509
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.320USD
Average target price
15.00USD
Spread / Average Target
+104.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!